Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical development company focused on advanced cancer treatments, announced it will release its full year 2024 financial results and provide a business update on March 26, 2025, after market close. The financial report and business update will be accessible through the company's website newsroom section.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda di sviluppo di radiopharmaceutici focalizzata su trattamenti avanzati per il cancro, ha annunciato che pubblicherà i suoi risultati finanziari per l'intero anno 2024 e fornirà un aggiornamento aziendale il 26 marzo 2025, dopo la chiusura del mercato. Il rapporto finanziario e l'aggiornamento aziendale saranno accessibili attraverso la sezione newsroom del sito web dell'azienda.
Perspective Therapeutics (NYSE AMERICAN: CATX), una empresa de desarrollo de radiofármacos centrada en tratamientos avanzados contra el cáncer, anunció que publicará sus resultados financieros del año completo 2024 y proporcionará una actualización del negocio el 26 de marzo de 2025, después del cierre del mercado. El informe financiero y la actualización del negocio estarán disponibles a través de la sección de sala de prensa en el sitio web de la empresa.
Perspective Therapeutics (NYSE AMERICAN: CATX), 고급 암 치료에 중점을 둔 방사성 의약품 개발 회사가 2024 회계연도 전체 재무 결과를 발표하고 2025년 3월 26일에 사업 업데이트를 제공할 것이라고 발표했습니다. 재무 보고서와 사업 업데이트는 회사 웹사이트의 뉴스룸 섹션을 통해 접근할 수 있습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de développement de radiopharmaceutiques axée sur les traitements avancés du cancer, a annoncé qu'elle publiera ses résultats financiers de l'année complète 2024 et fournira une mise à jour de l'entreprise le 26 mars 2025, après la fermeture du marché. Le rapport financier et la mise à jour de l'entreprise seront accessibles via la section salle de presse du site Web de l'entreprise.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Unternehmen für die Entwicklung von Radiopharmazeutika, das sich auf fortschrittliche Krebsbehandlungen konzentriert, gab bekannt, dass es seine Finanzergebnisse für das gesamte Jahr 2024 veröffentlichen und am 26. März 2025 nach Börsenschluss ein Unternehmensupdate bereitstellen wird. Der Finanzbericht und das Unternehmensupdate werden über den Nachrichtenbereich der Unternehmenswebsite zugänglich sein.
- None.
- None.
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and therapy trials in the U.S. for the treatment of metastatic melanoma and neuroendocrine tumors, respectively. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) release its 2024 annual financial results?
Where can investors access CATX's 2024 annual financial report?
What type of update will CATX provide along with its 2024 financial results?
What is Perspective Therapeutics' (CATX) main business focus?
